Real-world Evidence Study EvaLuating PAtient-Reported Outcomes With

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04993261` - An Investigational Scan (Dual Energy CT) in Detecting Gastrointestinal Carcinoid Tumors	Early Phase 1
Not yet recruiting	`NCT04039516` - Carcinoid Heart Disease and Peptide Receptor Radiotargetted Therapy	Phase 2
Completed	`NCT01234168` - A Study to Assess Neuroendocrine Tumour (NET) Patients Currently Treated by Somatuline Autogel for History of Carcinoid Syndrome Associated With Episodes of Diarrhea
Terminated	`NCT04073017` - Enterade in Carcinoid/Non-Carcinoid Syndrome Neuroendocrine Tumor Patients With Quality of Life Limiting Bowel Frequency	N/A
Recruiting	`NCT05756608` - Fibrosis in Chronic and Delayed Myocardial Infarction
Completed	`NCT00774930` - An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome	Phase 3
Withdrawn	`NCT04713202` - Prospective Assessment of Patients With Neuroendocrine Tumors and Current or Prior History of Carcinoid Syndrome or Diarrhea Undergoing Peptide Receptor Radionuclide Therapy With or Without Telotristat Ethyl	Phase 2
Completed	`NCT00853047` - Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome Not Managed by Stable-Dose Octreotide Therapy	Phase 2
Completed	`NCT02063659` - Telotristat Etiprate for Carcinoid Syndrome Therapy	Phase 3
Withdrawn	`NCT04776876` - Retifanlimab (INCMGA00012) and Telotristat Ethyl for the Treatment of Advanced Neuroendocrine Tumors and Carcinoid Syndrome	Phase 2
Recruiting	`NCT03453489` - AMT-PET in Monitoring Telotristat Etiprate Treatment in Participants With MetastaticNeuroendocrine Neoplasm	Phase 2
Active, not recruiting	`NCT05361668` - Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome	Phase 2
Completed	`NCT01104415` - Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome	Phase 2
Withdrawn	`NCT01172717` - Study of Panitumumab in the Treatment of Carcinoid Syndrome	Phase 2
Terminated	`NCT00884715` - Pharmacokinetics, Efficacy and Safety of an Octreotide Implant in Patients With Carcinoid Syndrome	Phase 1/Phase 2
Completed	`NCT01677910` - TELESTAR (Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome)	Phase 3
Completed	`NCT01430871` - Effects of Serotonin Excess on Bone in Carcinoid Syndrome	N/A
Completed	`NCT02026063` - Telotristat Etiprate - Expanded Treatment for Patients With Carcinoid Syndrome Symptoms	Phase 3
Terminated	`NCT01018953` - Study to Assess the Efficacy and Safety of Different Doses of BIM 23A760 in Patients With Carcinoid Syndrome	Phase 2
Terminated	`NCT04140409` - Sandostatin (Octreotide LAR) May Lead to Clinical Improvement Through Receptor Occupation Optimisation	Phase 4

NCT number	NCT03223428
Study type	Observational [Patient Registry]
Source	TerSera Therapeutics LLC
Contact
Status	Completed
Phase
Start date	June 22, 2017
Completion date	January 14, 2022

Real-world Evidence Study EvaLuating PAtient-Reported Outcomes With XERMELO — RELAX

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms